Beta Bionics (NASDAQ:BBNX) Stock Price Down 4.3% on Insider Selling

Beta Bionics, Inc. (NASDAQ:BBNX)’s stock price dropped 4.3% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $21.37 and last traded at $21.2260. Approximately 990,815 shares traded hands during trading, a decline of 16% from the average session volume of 1,178,910 shares. The stock had previously closed at $22.18.

Specifically, insider Mike Mensinger sold 2,650 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the sale, the insider directly owned 177,390 shares of the company’s stock, valued at $3,902,580. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 30,779 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the transaction, the insider directly owned 56,479 shares in the company, valued at $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BBNX shares. Robert W. Baird increased their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Wall Street Zen raised shares of Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday. UBS Group reiterated a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday. Finally, Bank of America boosted their target price on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and a consensus target price of $21.90.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

Beta Bionics Price Performance

The company has a fifty day simple moving average of $17.66 and a two-hundred day simple moving average of $14.05. The company has a market capitalization of $984.83 million, a P/E ratio of -13.27 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities analysts anticipate that Beta Bionics, Inc. will post -2.06 earnings per share for the current year.

Institutional Trading of Beta Bionics

Institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC bought a new stake in shares of Beta Bionics during the 2nd quarter worth $2,524,000. Bank of America Corp DE bought a new position in Beta Bionics in the 2nd quarter worth $8,566,000. Man Group plc acquired a new position in Beta Bionics during the 2nd quarter worth $419,000. Legal & General Group Plc bought a new stake in Beta Bionics during the second quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics in the second quarter valued at about $172,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.